Table 1.

Patient classification and response to combined treatment

FAB typeSer473 p-AktTRAIL-R2 up-regulatedP + T synergism, average CI (ED50 + ED75 + ED90)
M1#1++++++0.23 ± 0.03
M1#2+++0.51 ± 0.05
M2#10.95 ± 0.10
M2#2+++++++0.26 ± 0.04
M2#3+++++++0.15 ± 0.02
M2#41.08 ± 0.15
M2#5++/−0.84 ± 0.09
M2#60.99 ± 0.12
M2#7+++++0.39 ± 0.05
M4#1+++++++0.18 ± 0.02
  • NOTE: Patients were classified according to the French-American-British (FAB) classification. The levels of Ser473 p-Akt and TRAIL-R2 were evaluated by flow cytometry and/or Western blotting. A CI < 0.9 was considered synergistic, whereas a CI between 0.9 and 1.1 was considered additive. Results are from three different experiments ± SD.

    Abbreviations: P, perifosine; T, TRAIL; ED, effective dose.